ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 689.1 | 672.9 | 649.5 |
| Other income | 22.8 | 13.9 | 10.1 |
| Total income | 711.9 | 686.8 | 659.6 |
| Profit before exceptional items & tax | 215.8 | 224.0 | 191.3 |
| Exceptional items | 0.0 | 25.7 | 0.0 |
| Profit before tax | 215.8 | 198.4 | 191.3 |
| Net profit | 162.7 | 150.3 | 141.9 |
| Operating margin | 30.3% | 28.9% | 29.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.70% |
|---|---|
| Net profit, quarter on quarter | +8.30% |
| Revenue, year on year | +6.10% |
NSE results filing, NSE: ALIVUS. Figures extracted from the filing.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,460.60
- Market cap
- ₹17,961 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 26.8×Sector 43.7×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Acquisition
Alivus Life Sciences signed a Shareholders' Agreement with IQGEN-X Pharma and its continuing shareholders. It governs inter se rights after the company's 76% IQGEN-X stake purchase.
Alivus Life Sciences Promoter Selling
Nirma Limited, a promoter of Alivus Life Sciences, sold 36,80,000 shares (2.99%) in the open market on 6 November 2026. Promoter holding falls from 74.73% to 71.74%.
Alivus Life Sciences Earnings Call Transcript: Key Takeaways
Alivus reported strong revenue growth driven by new products and CDMO traction, though margins were inflated by one-time income.
- Call
- Guides 11% growth
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.